Teva and Medincell Secure EMA Filing Acceptance for TEV-749 Long-Acting Schizophrenia Injectable

Teva Pharmaceuticals and Medincell have cleared a critical regulatory checkpoint in Europe, with the European Medicines Agency accepting the marketing authorisation application for TEV-749, a subcutaneous long-acting injectable (LAI) formulation of risperidone intended for schizophrenia. For regulatory affairs leads tracking LAI submissions in the EU, the acceptance signals that the dossier met EMA's threshold for completeness, a bar that carries particular weight for depot formulations with complex CMC profiles.

TEV-749 is built on Medincell's BEPO platform, a biodegradable polymer-based subcutaneous depot technology designed to deliver controlled drug release over an extended period. From a manufacturing standpoint, BEPO-based products present distinct process validation challenges: polymer excipient characterisation, in-vitro release method development, and sterility assurance for a terminally sterile or aseptically filled depot matrix all require robust justification under ICH Q8/Q9/Q10 principles. The EMA's willingness to proceed to review implies those sections of the dossier were sufficiently substantiated.

The clinical rationale centres on adherence. Oral antipsychotics carry well-documented real-world compliance gaps; a monthly or longer-cycle subcutaneous depot reduces the administration burden without requiring intramuscular injection, which has historically limited LAI uptake in outpatient settings. If approved, TEV-749 would be among the first subcutaneous risperidone LAIs on the European market, adding a formulation option that QA and supply teams at hospital and community pharmacy level would need to accommodate within cold-chain and handling protocols.

For plant heads and QA directors at contract or captive sterile fill-finish sites, the progression of BEPO-platform products through major regulatory agencies is worth monitoring. Depot polymer formulations occupy a manufacturing complexity tier above standard lyophilised injectables, and EMA review outcomes, including any Day 120 or Day 180 List of Questions, will set precedent for how the agency interprets process controls and release specifications for this class.

The EMA review clock is now running, with a standard centralised procedure timeline of approximately 210 active review days, meaning a Committee for Medicinal Products for Human Use (CHMP) opinion could be anticipated within the next 12 to 15 months barring clock stops.

Source: Media4Growth via Indian Pharma Post, 24 May 2026.